Adbry for Atopic Dermatitis

Adbry is the brand name for tralokinumab-ldrm. It is approved for the treatment of atopic dermatitis, commonly referred to as eczema, a chronic skin condition characterized by itching, redness, and inflammation. Adbry is approved for those with moderate-to-severe atopic dermatitis who have not responded well to other treatments. Tralokinumab is a monoclonal antibody, a type… Read More